首页> 美国卫生研究院文献>The World Allergy Organization Journal >Asthma Treatment: 192 Efficacy and Safety of Combined Mometasone Furoate/Formoterol 100/10ìG Twice Daily in Subjects with Asthma Inadequately Controlled on Low-Dose Inhaled Corticosteroids
【2h】

Asthma Treatment: 192 Efficacy and Safety of Combined Mometasone Furoate/Formoterol 100/10ìG Twice Daily in Subjects with Asthma Inadequately Controlled on Low-Dose Inhaled Corticosteroids

机译:哮喘治疗:氟哌酸莫米松/福莫特罗100 /10ìG联合使用对低剂量吸入性糖皮质激素控制不佳的受试者每日两次两次的疗效和安全性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAsthma is a variable disease. Optimal control in clinical practice often requires the use of therapy at varying doses. Availability of treatments at multiple strengths is therefore essential. These are results from a 6-month trial of combined mometasone furoate/formoterol (MF/F) 100/10 μg administered via a metered-dose inhaler (MDI) as treatment for asthma deterioration (ie, severe asthma exacerbation) and bronchoconstriction in asthmatics previously treated with low-dose inhaled corticosteroids (ICS).
机译:背景哮喘是一种多变的疾病。临床实践中的最佳控制通常需要使用不同剂量的疗法。因此,以多种优势提供治疗至关重要。这些是通过计量吸入器(MDI)联合应用100/10μg糠酸莫米松/福莫特罗(MF / F)进行的为期6个月的试验的结果,该药物用于治疗哮喘患者的哮喘恶化(即严重哮喘加重)和支气管狭窄以前用小剂量吸入皮质类固醇(ICS)治疗。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号